MMV Launches Malaria Injectable Trial in Rwanda
The trial of MMV371, a long-acting injectable drug for malaria prevention, has commenced in Rwanda, representing a significant advancement in combating malaria. Medicines for Malaria Venture (MMV) and Rinda Ubuzima announced this Phase 1 study, which is the first of its kind in Africa.
If successful, MMV371 could enhance existing malaria prevention strategies. The World Health Organisation reported over 280 million malaria cases and 600,000 deaths globally in 2024, with 95 percent of deaths occurring in Africa.
The trial will assess the safety and tolerability of MMV371 in Rwandan adults and adolescents, building on previous research in the UK that indicated the drug could provide protection for approximately three months. Dr Martin Fitchet, CEO of MMV, emphasized the necessity of new prevention technologies for malaria elimination, stating that long-acting injectables could transform malaria prevention by offering sustained protection through a single administration.
Plus234Feed summary based on reporting from Leadership Newspaper. Read the original report below.
Read full article
Continue on Leadership Newspaper
Get the week in one email
Top stories, NPFL results, the naira, every Friday morning. Free, one email a week.
Related Stories
Rwanda Launches Africa's First Injectable Malaria Drug Trial
DR Congo Launches Ebola Prevention Drug Trial
WHO Launches Ebola Vaccine Trial in DR Congo
Kogi launches first net distribution drive in 9 years to fight malaria
Malaria Consortium's Ojelade Calls for Political Will in Nigeria
Kenya allocates $2 million for Ebola response efforts
Get Plus234Feed on messaging apps
Same headlines, delivered where you already scroll.
